Wagner M. Zago
Chief Scientific OfficerDr. Wagner M. Zago, Ph.D has been Chief Scientific Officer of Prothena Corporation plc since June 12, 2017. Prior to that, Dr. Zago was Vice President and Head of Research at Prothena Corporation since 2015. Dr. Zago joined Prothena in 2012, when Prothena was founded after spinning out of Elan Pharmaceuticals, first as Head of Pharmacology and Neuropathology from 2012 to 2015 and more recently as Vice President, Head of Research. Before Prothena, he was a Principal Scientist at Elan Pharmaceuticals performing research aimed at developing new therapeutics for CNS disorders, including beta amyloid-targeted therapies and supportive research for the development of natalizumab, which was commercialized by Biogen for relapsing multiple sclerosis. From 2006 to 2012, he held various scientific positions at Elan Pharmaceuticals, Inc, performing research aimed at developing new therapeutics for central nervous system disorders and inflammation. While in this position, from 2009 to 2013, he served as a Scientist at Janssen Alzheimer Immunotherapy, where he made significant discoveries about vascular changes associated with anti-beta amyloid immunotherapy. Dr. Zago holds several key patents and has published broadly in the areas of protein immunotherapy and central nervous system (CNS) disorders. Previously, he was a Postdoctoral Researcher at the University of California, San Diego and the Burnham Institute. Dr. Zago earned his BS in Biomedicine from the Universidade Federal de Sao Paulo (Escola Paulista de Medicina), Brazil, and his MS and PhD (both in Pharmacology) from the Universidade de Sao Paulo, Brazil, and was a Post-Doctoral Researcher at the University of California, San Diego and the Burnham Institute.
公司職務
- 公司名稱Prothena Corporation plc股票代碼PRTA職務Chief Scientific Officer共事同僚
- GGGene G. KinneyPresident, CEO & Director
- DGDaniel G. WelchIndependent Chairman
- TBTran B. NguyenChief Financial Officer
- BSBrandon S. SmithChief Operating Officer
- KLKarin L. WalkerChief Accounting Officer & Controller
- LGLars Gosta EkmanIndependent Chair Emeritus
- RTRichard T. CollierIndependent Director
- SMShane Martin CookeIndependent Director
